Apogee Therapeutics APGE

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.70 (+1.98%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Apogee Therapeutics (APGE)
    Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $36.14

    • Market Cap

      $2.10 Billion

    • Price-Earnings Ratio

      -14.93

    • Total Outstanding Shares

      46.02 Million Shares

    • Total Employees

      196

    • Dividend

      No dividend

    • IPO Date

      July 14, 2023

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      221 crescent st., Waltham, MA, 02453

    • Homepage

      https://www.apogeetherapeutics.com

    Historical Stock Splits

    If you bought 50 shares of APGE before January 8, 2008, you'd have 1 share today.
    Execution DateSplit Amount
    January 8, 20081-for-50 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Investing Activities$-386.52 Million
    Net Cash Flow From Operating Activities$-133.21 Million
    Net Cash Flow, Continuing$-69.19 Million
    Net Cash Flow From Operating Activities, Continuing$-133.21 Million
    Net Cash Flow$-69.19 Million
    Net Cash Flow From Investing Activities, Continuing$-386.52 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Operating Income/Loss$-178.14 Million
    Net Income/Loss Available To Common Stockholders, Basic$-146.66 Million
    Income/Loss From Continuing Operations Before Tax$-146.66 Million
    Basic Average Shares$171.30 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Preferred Stock Dividends And Other Adjustments$0

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$-45.27 Million
    Comprehensive Income/Loss$-142.91 Million
    Comprehensive Income/Loss Attributable To Parent$-143.53 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Noncurrent Liabilities$9.27 Million
    Equity$734.40 Million
    Other Non-current Assets$240.39 Million
    Accounts Payable$2.22 Million
    Equity Attributable To Noncontrolling Interest$0
    Liabilities$41.88 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about APGE from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.